Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
about
Pathogenesis of myasthenia gravis: update on disease types, models, and mechanismsAnimal models of myasthenia gravis: utility and limitationsClinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological SocietyThe role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravisMapping autoantigen epitopes: molecular insights into autoantibody-associated disorders of the nervous systemPyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-specific kinase autoantibodyEffects of the ß2-adrenoceptor agonist, albuterol, in a mouse model of anti-MuSK myasthenia gravisAutoantibodies to agrin in myasthenia gravis patients.Myasthenia gravis: an update for the clinician.Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis.Altered active zones, vesicle pools, nerve terminal conductivity, and morphology during experimental MuSK myasthenia gravisCurrent and emerging therapies for the treatment of myasthenia gravis.Plasma exchange for myasthenia gravis.Characterization of B cells in muscle-specific kinase antibody myasthenia gravis.The neuromuscular junction: measuring synapse size, fragmentation and changes in synaptic protein density using confocal fluorescence microscopy.Anti-MuSK autoantibodies block binding of collagen Q to MuSK.Flow Cytofluorimetric Analysis of Anti-LRP4 (LDL Receptor-Related Protein 4) Autoantibodies in Italian Patients with Myasthenia Gravis.Muscle autoantibodies in myasthenia gravis: beyond diagnosis?Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.Forced expression of muscle specific kinase slows postsynaptic acetylcholine receptor loss in a mouse model of MuSK myasthenia gravisLG2 agrin mutation causing severe congenital myasthenic syndrome mimics functional characteristics of non-neural (z-) agrin.Muscle-specific receptor tyrosine kinase antibody positive myasthenia gravis current status.MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters.Autoimmune myasthenia gravis: emerging clinical and biological heterogeneityThe effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates.Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis.Stable expression of human muscle-specific kinase in HEp-2 M4 cells for automatic immunofluorescence diagnostics of myasthenia gravis.Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes.Rituximab therapy in pemphigus and other autoantibody-mediated diseases.Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.Neural antigen-specific autoimmune disorders.Structure of the neuromuscular junction: function and cooperative mechanisms in the synapse.Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis.Autoantibodies to neurotransmitter receptors and ion channels: from neuromuscular to neuropsychiatric disorders.Pathogenic immune mechanisms at the neuromuscular synapse: the role of specific antibody-binding epitopes in myasthenia gravis.Myasthenia gravis: recent advances in immunopathology and therapy.B-cell-activating factor and autoimmune myasthenia gravis.Autoimmune Thyroiditis and Myasthenia Gravis.Animal models of antimuscle-specific kinase myasthenia.Antibodies to low density lipoprotein receptor-related protein 4 in seronegative myasthenia gravis.
P2860
Q26740634-3E3F9345-F0AA-4242-9F0A-F08900D24020Q26750632-11AFFA57-1189-40C8-B635-C13DE0E688F4Q26765172-44705325-DE35-4076-A2E7-1770C328AFC5Q27008264-F3CB8495-C23F-4E42-B20B-15A29A0E14AAQ28075974-ED3CA53B-D649-40B4-96D7-FD9697A9F67DQ28286248-0643436D-1DE3-4B42-A744-193605F27E01Q28539518-945201C1-2DBF-4BEA-A769-CFE31A4B2825Q34040180-4113DEA7-BEE6-4107-A646-0AD916B0C21EQ34377145-6CE1140E-3E98-4511-A0CF-FF7C4DB4675EQ34503367-F8A87668-D3C7-4C4A-BBB1-C89F62603573Q34599589-50E5D728-4D21-4330-8259-4304498A2716Q34879129-BCD82C6D-63BE-4C22-86E9-1FCC4A17D166Q35041815-2E197821-908F-4596-AB96-ECA695438669Q35134860-A58A8572-E01D-4D42-9971-BA6B5968190BQ35161802-CD105645-B3CC-43E2-B857-28813F5BE6DFQ35599522-0835518F-5A8F-46BC-A48C-5BEC614B22C9Q35748796-3E107255-E5A8-474F-A959-D823969E7954Q36420763-9D218687-D8CE-40DD-9DDE-5F80219C7324Q36484383-1D05004F-EE93-41EA-B428-234E95432C2EQ36597860-AD6B0687-B5C1-48D2-90D8-E22C1C840432Q36696606-18F7BBAE-C44B-4900-A41E-28FA9F67CDFAQ37252133-EDCDC601-11D8-46AB-8FF1-3642AC23802EQ37288598-3FA5693F-1C9F-40B1-8966-CD2ED960BC04Q37315963-C41BA9F3-5AF3-47EE-9CD1-1722F8663DC1Q37362084-66B4B39B-2CEF-4FE4-8357-ABC77CBFA58DQ37384090-8CBB60D6-7D41-4814-9707-6BAA2F6DDF80Q37458471-9EDC8049-2E01-45D3-B470-8D902A80B9DDQ37561515-265501D5-B6DE-417B-B70E-124EC6A512CDQ37620483-53DE0D28-BA1B-4B50-9921-A4F9B317350BQ37727994-958B4FDB-0550-4026-9DA9-30A7E2E77E8AQ38020960-7AA341C1-7989-47AA-A60E-41B5DB9D7D1EQ38068531-DEEABA8F-3FD0-4F6F-8F59-8DC862A0C87DQ38070761-7960FAC9-93A1-4895-A01A-7EF1F3F14D5CQ38143031-615224AF-6352-4134-B707-3CFCCCDD5E36Q38161532-0C52206B-1B0A-48D5-9DD7-DD866F6FD70EQ38969032-81F3DC97-DCCF-49A2-91D8-26B3178A6EDDQ40179681-85EF9F61-0D30-4EB5-819D-915FDF0156F6Q40999568-FBB05CBB-82FA-4F15-A29B-E175390AE7E5Q41846302-66FF37C9-3049-4BE3-AEB9-4620F3AA4239Q42733578-45FA2171-5000-4A2D-92DB-E08E10954079
P2860
Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
@ast
Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
@en
Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
@nl
type
label
Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
@ast
Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
@en
Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
@nl
prefLabel
Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
@ast
Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
@en
Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
@nl
P2860
P356
P1433
P1476
Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
@en
P2093
Othon L Gervásio
Rebecca N Cole
P2860
P304
P356
10.1002/ANA.21371
P577
2008-06-01T00:00:00Z